{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:40:46Z","timestamp":1787964046530,"version":"build-2784847793"},"reference-count":30,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"European Urology Scholarship Programme"},{"DOI":"10.13039\/100004331","name":"Johnson&Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Next-generation imaging (NGI), particularly with prostate-specific membrane antigen positron emission tomography (PSMA PET) tracers, enables earlier and more accurate detection of metastases. However, conventional imaging (CT and bone scan) remains more affordable and widely accessible and was the standard used in most pivotal trials that established current survival outcomes. As PSMA PET becomes more widely adopted, a stage migration effect is emerging. However, key uncertainties persist regarding the actual proportional employment of NGI in clinical practice, main indications for its use and the mid-term and long-term effects of an NGI-driven treatment pathway. Furthermore, when or whether CI alone might remain enough informative for the treatment decision-making is still unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The European Registry of Next-Generation Imaging in Advanced Prostate Cancer is a non-profit, non-interventional, multi-centre, international, prospective, investigator-initiated registry that is intended to collect real-world data on how patients with prostate cancer at risk of harbouring metastasis (high-risk at initial diagnosis, or after primary treatment) are managed according to the type of imaging used for the systemic work-up. The registry is conducted in two phases: (1) cross-sectional analysis of imaging choices and their effect on clinical decision-making and (2) longitudinal follow-up evaluating survival outcomes such as progression-free survival (PFS), disease-specific survival (DSS) and skeletal-related events (SSEs). Statistical analyses will include descriptive analysis of demographic and clinical variables, comparative analysis between different imaging pathways, survival and prognostic analyses using Kaplan\u2013Meier tests. The expected minimum sample size of the registry is 600 patients, and the planned follow-up duration is 24 months for the longitudinal follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol was approved by the ethics committee of Fundaci\u00f3 Puigvert (#C2024\/30), and ethics approval is required at all participating sites. All patients will provide written informed consent. The results will be disseminated widely and transparently to maximise their effect on clinical practice, research and patient care through peer-reviewed publications, presentations at international conferences as well as through patient advocacy groups and relevant patient websites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06866782\">NCT06866782<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106022","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:21:29Z","timestamp":1764786089000},"page":"e106022","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["European Registry of Next Generation Imaging in Advanced Prostate Cancer (RING): protocol for an international, prospective registry study"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06866782","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0469-7007","authenticated-orcid":false,"given":"Daria","family":"Chernysheva","sequence":"first","affiliation":[{"name":"Urooncology, Fundacio Puigvert, Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[{"name":"IRCCS AOU Bologna, Bologna, Italy"},{"name":"University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[{"name":"Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[{"name":"Department of Urology, Luzerner Kantonsspital, Lucerne, LU, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[{"name":"Fundacio Puigvert, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[{"name":"Fundacio Puigvert, Barcelona, Spain"},{"name":"Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R","family":"Padhani","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre, Northwood, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-7060","authenticated-orcid":false,"given":"Francesco","family":"Sanguedolce","sequence":"additional","affiliation":[{"name":"Urology, Fundacio Puigvert, Barcelona, Barcelona, Spain"},{"name":"Department of Medicine, Surgery and Pharmacy, Universita degli Studi di Sassari, Sassari, Sardinia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2026010703454092000_15.12.e106022.1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.euf.2016.06.018","article-title":"Rationale for Modernising Imaging in Advanced Prostate Cancer","volume":"3","author":"Padhani","year":"2017","journal-title":"Eur Urol Focus"},{"key":"2026010703454092000_15.12.e106022.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.03.001"},{"key":"2026010703454092000_15.12.e106022.3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","article-title":"Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)","volume":"84","author":"Surasi","year":"2023","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268555"},{"key":"2026010703454092000_15.12.e106022.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265205"},{"key":"2026010703454092000_15.12.e106022.6","unstructured":"EAU-eanm-estro-esur-isup-siog-guidelines-on-prostate-cancer-2025_2025-03-24-120144_rinw."},{"key":"2026010703454092000_15.12.e106022.7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JU.0000000000001592","article-title":"The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer","volume":"205","author":"Meijer","year":"2021","journal-title":"J Urol"},{"key":"2026010703454092000_15.12.e106022.8","doi-asserted-by":"crossref","unstructured":"Incesu R-B , Preisser F , Nohe F , et al . Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer. Prostate Cancer Prostatic Dis 2025. doi:10.1038\/s41391-024-00930-z","DOI":"10.1038\/s41391-024-00930-z"},{"key":"2026010703454092000_15.12.e106022.9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/pros.24884","article-title":"Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET","volume":"85","author":"Esen","year":"2025","journal-title":"Prostate"},{"key":"2026010703454092000_15.12.e106022.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","article-title":"Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard","volume":"5","author":"Stabile","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2026010703454092000_15.12.e106022.11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.13","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049"},{"key":"2026010703454092000_15.12.e106022.15","doi-asserted-by":"crossref","unstructured":"Hofman MS , Kasivisvanathan V , Link E , et al . Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography\/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial. European Urology Oncology 2024. doi:10.1016\/j.euo.2024.11.006","DOI":"10.1016\/j.euo.2024.11.006"},{"key":"2026010703454092000_15.12.e106022.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268441"},{"key":"2026010703454092000_15.12.e106022.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2026010703454092000_15.12.e106022.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3"},{"key":"2026010703454092000_15.12.e106022.19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eururo.2022.10.005","article-title":"More Accurate Imaging Is Not Stage Migration: Time To Move from \u201cHubble\u201d to \u201cWebb\u201d in Hormone-sensitive Prostate Cancer","volume":"83","author":"Ayati","year":"2023","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography\/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"4","author":"von Eyben","year":"2018","journal-title":"Eur Urol Focus"},{"key":"2026010703454092000_15.12.e106022.21","doi-asserted-by":"crossref","first-page":"102404","DOI":"10.1016\/j.clgc.2025.102404","article-title":"The Influence of the Introduction of PSMA-PET\/CT in Danish Men Diagnosed with Prostate Cancer","volume":"23","author":"Stroomberg","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"2026010703454092000_15.12.e106022.22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2022.10.024","article-title":"Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer","volume":"83","author":"Bukavina","year":"2023","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.eururo.2025.04.017","article-title":"Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study","volume":"88","author":"Karpinski","year":"2025","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.195255"},{"key":"2026010703454092000_15.12.e106022.26","article-title":"The PRIMARY Score: Using intra-prostatic PSMA PET\/CT patterns to optimise prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"2026010703454092000_15.12.e106022.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"2026010703454092000_15.12.e106022.28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"2026010703454092000_15.12.e106022.29","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.euo.2023.11.019","article-title":"Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer","volume":"7","author":"Ni","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026010703454092000_15.12.e106022.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.02.001"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:46:06Z","timestamp":1767786366000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-106022"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106022","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}